Ocular Therapeutix Inc (OCUL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has a cash flow conversion efficiency ratio of -0.129x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.27 Million) by net assets ($520.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ocular Therapeutix Inc market cap and net worth for the company's overall valuation and market capitalisation.
Ocular Therapeutix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ocular Therapeutix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocular Therapeutix Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Ocular Therapeutix Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bayside Land Corporation Ltd
TA:BYSD
|
0.039x |
|
ZhongAn Online P & C Insurance Co. Ltd
F:1ZO
|
0.032x |
|
INOX India Limited
NSE:INOXINDIA
|
0.063x |
|
Liontown Resources Limited
F:LIS
|
-0.010x |
|
Flywire Corp
NASDAQ:FLYW
|
0.026x |
|
Ora Banda Mining Ltd
AU:OBM
|
0.452x |
|
Vincom Retail JSC
VN:VRE
|
-0.005x |
|
Fraser Neave Holdings Bhd
KLSE:3689
|
0.027x |
Annual Cash Flow Conversion Efficiency for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocular Therapeutix Inc from 2012 to 2025. View Ocular Therapeutix Inc (OCUL) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $654.31 Million | $-204.88 Million | -0.313x | +26.68% |
| 2024-12-31 | $315.34 Million | $-134.68 Million | -0.427x | +44.58% |
| 2023-12-31 | $91.13 Million | $-70.23 Million | -0.771x | +54.25% |
| 2022-12-31 | $35.38 Million | $-59.60 Million | -1.685x | -126.17% |
| 2021-12-31 | $88.00 Million | $-65.55 Million | -0.745x | -5.84% |
| 2020-12-31 | $76.09 Million | $-53.55 Million | -0.704x | -103.29% |
| 2019-12-31 | $-3.63 Million | $-77.58 Million | 21.371x | +1657.47% |
| 2018-12-31 | $35.88 Million | $-49.23 Million | -1.372x | +28.92% |
| 2017-12-31 | $26.15 Million | $-50.47 Million | -1.930x | -195.27% |
| 2016-12-31 | $52.01 Million | $-34.00 Million | -0.654x | -73.58% |
| 2015-12-31 | $89.59 Million | $-33.74 Million | -0.377x | -7.86% |
| 2014-12-31 | $58.70 Million | $-20.50 Million | -0.349x | -264.23% |
| 2013-12-31 | $-59.47 Million | $-12.64 Million | 0.213x | -21.25% |
| 2012-12-31 | $-46.61 Million | $-12.59 Million | 0.270x | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more